[Use of clindamycin-2-phosphate in ophthalmology (author's transl)].
Clindamycin-2-phosphate was studied to evaluate its possible use in ophthalmology. 1. Sensitivity of organisms isolated from human clinical materials: Of 44 staphylococcal strains in vitro studied 13 were highly sensitive to 0.1 mug/ml and 28 were resistant to 100 mug/ml or more of clindamycin-2-phosphate. 2. In experiments with rabbits, clindamycin-2-phosphate showed superior penetration into the ocular tissues after intravenous injection than after intramuscular injection. 3. Clindamycin-2-phosphate was administered intramuscularly at the dose of 300 mg to 6 healthy volunteers. The blood concentrations of 6 cases averaged 3.2 mug/ml after 1 hour, and 0.8 mug/ml after 6 hours. 4. Fourteen patients with extraocular infection were treated with daily intramuscular administration of 300 mg of clindamycin-2-phosphate. All of them improved by the treatment, and no side effect was observed.
D000328:Adult; D000368:Aged; D000818:Animals; D002648:Child; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D003316:Corneal Diseases / Q000188:drug therapy; D003320:Corneal Ulcer / Q000188:drug therapy; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D006726:Hordeolum / Q000188:drug therapy; D006801:Humans; D008297:Male; D008837:Micrococcus / Q000187:drug effects; D008875:Middle Aged; D009943:Organophosphorus Compounds; D011817:Rabbits; D013210:Staphylococcus / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects
D009943:Organophosphorus Compounds; D002981:Clindamycin